乳腺癌自然史及肿瘤生长速度的研究进展

doi:10.12114/j.issn.1007-9572.2021.02.002

摘要/Abstract

摘要： 在发达国家，乳腺癌早期筛查已作为卫生服务的一部分。乳腺癌筛查效果受筛查间期的影响较大，筛查间期又取决于目标人群的乳腺癌自然史及肿瘤生长速度。本文系统回顾了国内外有关乳腺癌自然史的研究，并针对肿瘤进展过程中最重要的参数即肿瘤生长速度及其影响因素进行分析，得出目前乳腺癌自然史进展模型多采用不可检测期、临床前期、临床期和死亡及其基础上考量更多肿瘤生长特征、参数构建的多状态模型；乳腺肿瘤生长速度采用临床前期逗留时间和肿瘤体积倍增时间进行评估；乳腺肿瘤生长速度又受年龄、BRCA 1/2基因突变、乳腺癌家族史和其他传统危险因素及肿瘤组织病理学、临床信息等诸多特征的影响。了解乳腺肿瘤的生长模式及其影响因素可为制定最佳的乳腺癌筛查策略、提高早期筛查效果提供参考依据；同时肿瘤的生长速度又影响乳腺癌患者生存情况，有效评估肿瘤增长情况也可为临床开发新的治疗策略及制定个性化筛查间期提供参考依据。

关键词: 乳腺肿瘤, 自然史, 生长速度, 逗留时间, 肿瘤体积倍增时间, 综述

Abstract: In developed countries，early screening for breast cancer is already part of health services. The screening effect is greatly affected by the screening interval，which is determined by the natural history and tumor growth rate of breast cancer in the target population. In this review，we systematically reviewed the previous global studies on natural history of breast cancer，analyzed the most important parameter of tumor progression，namely，tumor growth rate，and its influencing factors，and summarized that most natural history progression models of breast cancer are multi-phased，usually covering four-phases of non-detectable，pre-clinical，clinical and death，with more potentially associated tumor characteristic parameters incorporated；the growth rate of breast tumor is assessed by pre-clinical sojourn time and doubling time；tumor growth rate is influenced by age，BRCA1/2 gene mutation，family history of breast cancer，other traditional breast cancer risk factors，tumor histopathology features，other clinical information and so on. Understanding the growth pattern of breast cancer and its influencing factors will help to formulate the optimal screening strategy and improve early screening effects. As tumor growth rate is associated with the survival of breast cancer patients，effective assessment of tumor growth will give support to develop new treatment strategies and personalized screening interval.

Key words: Breast neoplasms, Natural history, Growth rate, Sojourn time, Tumor volume doubling time, Review

高鹰,魏玮,张鹏,等. 乳腺癌自然史及肿瘤生长速度的研究进展[J]. 中国全科医学, 2021, 24(30): 3794-3798. DOI: 10.12114/j.issn.1007-9572.2021.02.002.
GAO Ying,WEI Wei,ZHANG Peng, et al. Latest Developments in Natural History and Tumor Growth Rate of Breast Cancer　[J]. Chinese General Practice, 2021, 24(30): 3794-3798. DOI: 10.12114/j.issn.1007-9572.2021.02.002.

参考文献

［1］KUSAMA S，SPRATT J S Jr，DONEGAN W L，et al. The cross rates of growth of human mammary carcinoma［J］．Cancer，1972，30（2）：594-599．DOI：10.1002/1097-0142（197208）30：2<594：aid-cncr2820300241>3.0.co；2-2.
［2］FRIBERG S，MATTSON S.On the growth rates of human malignant tumors：implications for medical decision making［J］．J Surg Oncol，1997，65（4）：284-297．DOI：10.1002/（sici）1096-9098（199708）65：4<284：aid-jso11>3.0.co；2-2.
［3］DUFFY S W，CHEN H H，TABAR L，et al. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase［J］．Stat Med，1995，14（14）：1531-1543．DOI：10.1002/sim.4780141404.
［4］LEE S，HUANG H，ZELEN M.Early detection of disease and scheduling of screening examinations［J］．Stat Methods Med Res，2004，13（6）：443-456．DOI：10.1191/0962280204sm377ra.
［5］TAGHIPOUR S，BANJEVIC D，MILLER A B，et al. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study［J］．Br J Cancer，2013，108（3）：542-548．DOI：10.1038/bjc.2012.596.
［6］LAI M S，YEN M F，KUO H S，et al. Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases：Taiwan multicentre cancer screening （TAMCAS）［J］．Int J Cancer，1998，78（1）：21-26．DOI：10.1002/（sici）1097-0215（19980925）78：1<21：aid-ijc5>3.0.co；2-z.
［7］WU J C Y，HAKAMA M，ANTTILA A，et al. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data：subsidiary analysis of effects of inter-screening interval，sensitivity，and attendance rate on reduction of advanced cancer［J］．Breast Cancer Res Treat，2010，122（2）：553-566．DOI：10.1007/s10549-009-0701-x.
［8］TAN K H，SIMONELLA L，WEE H L，et al. Quantifying the natural history of breast cancer［J］．Br J Cancer，2013，109（8）：2035-2043．DOI：10.1038/bjc.2013.471.
［9］WU Y Y，YEN M F，YU C P，et al. Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates［J］．Risk Anal，2014，34（2）：367-379．DOI：10.1111/risa.12116.
［10］FRYBACK D G，STOUT N K，ROSENBERG M A，et al. The Wisconsin breast cancer epidemiology simulation model［J］．J Natl Cancer Inst Monogr，2006（36）：37-47．DOI：10.1093/jncimonographs/lgj007.
［11］ALAGOZ O，ERGUN M A，CEVIK M，et al. The University of Wisconsin Breast Cancer Epidemiology Simulation Model：an update［J］．Med Decis Making，2018，38（1_suppl）：99S-111．DOI：10.1177/0272989x17711927.
［12］WONG I O，KUNTZ K M，COWLING B J，et al. Cost effectiveness of mammography screening for Chinese women［J］．Cancer，2007，110（4）：885-895．DOI：10.1002/cncr.22848.
［13］KIM J K，KIM H D，JUN M J，et al. Correction to：tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma［J］．Dig Dis Sci，2017，62（11）：3259．DOI：10.1007/s10620-017-4785-6.
［14］KIM J K，KIM H D，JUN M J，et al. Tumor volume doubling time as a dynamic prognostic marker for patients with hepatocellular carcinoma［J］．Dig Dis Sci，2017，62（10）：2923-2931．DOI：10.1007/s10620-017-4708-6.
［15］SABRA M M，SHERMAN E J，TUTTLE R M.Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic，follicular cell-derived thyroid carcinoma［J］．Cancer，2017，123（15）：2955-2964．DOI：10.1002/cncr.30690.
［16］WEEDON-FEKJAER H，LINDQVIST B H，VATTEN L J，et al. Breast cancer tumor growth estimated through mammography screening data［J］．Breast Cancer Res，2008，10（3）：R41．DOI：10.1186/bcr2092.
［17］TAGHIPOUR S，CAUDRELIER L N，MILLER A B，et al. Using simulation to model and validate invasive breast cancer progression in women in the study and control groups of the Canadian National Breast Screening StudiesⅠandⅡ［J］．Med Decis Making，2017，37（2）：212-223．DOI：10.1177/0272989X16660711.
［18］BREKELMANS C T，WESTERS P，FABER J A，et al. Age specific sensitivity and sojourn time in a breast cancer screening programme （DOM） in The Netherlands：a comparison of different methods［J］．J Epidemiol Community Health，1996，50（1）：68-71．DOI：10.1136/jech.50.1.68.
［19］TABAR L，FAGERBERG G，CHEN H H，et al. Efficacy of breast cancer screening by age.New results from the Swedish Two-County Trial［J］．Cancer，1995，75（10）：2507-2517．DOI：10.1002/1097-0142（19950515）75：10<2507：aid-cncr2820751017>3.0.co；2-h.
［20］PACI E，DUFFY S W.Modelling the analysis of breast cancer screening programmes：sensitivity，lead time and predictive value in the Florence District Programme （1975—1986）［J］．Int J Epidemiol，1991，20（4）：852-858．DOI：10.1093/ije/20.4.852.
［21］JIANG H，WALTER S D，BROWN P E，et al. Estimation of screening sensitivity and sojourn time from an organized screening program［J］．Cancer Epidemiol，2016，44：178-185．DOI：10.1016/j.canep.2016.08.021.
［22］TABBANE F，BAHI J，RAHAL K，et al. Inflammatory symptoms in breast cancer.Correlations with growth rate，clinicopathologic variables，and evolution［J］．Cancer，1989，64（10）：2081-2089．DOI：10.1002/1097-0142（19891115）64：10<2081：aid-cncr2820641019>3.0.co；2-7.
［23］KUROISHI T，TOMINAGA S，MORIMOTO T，et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening［J］．Jpn J Cancer Res，1990，81（5）：454-462．DOI：10.1111/j.1349-7006.1990.tb02591.x.
［24］LUNDGREN B.Observations on growth rate of breast carcinomas and its possible implications for lead time［J］．Cancer，1977，40（4）：1722-1725．DOI：10.1002/1097-0142（197710）40：4<1722：aid-cncr2820400448>3.0.co；2-2.
［25］VON FOURNIER D，WEBER E，HOEFFKEN W，et al. Growth rate of 147 mammary carcinomas［J］．Cancer，1980，45（8）：2198-2207．DOI：10.1002/1097-0142（19800415）45：8<2198：aid-cncr2820450832>3.0.co；2-7.
［26］PEER P G，VAN DIJCK J A，HENDRIKS J H，et al. Age-dependent growth rate of primary breast cancer［J］．Cancer，1993，71（11）：3547-3551．DOI：10.1002/1097-0142（19930601）71：11<3547：aid-cncr2820711114>3.0.co；2-c.
［27］OTTEN J D，VAN SCHOOR G，PEER P G，et al. Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population［J］．J Med Screen，2018，25（1）：40-46．DOI：10.1177/0969141316687791.
［28］马恒敏，王乐，石菊芳，等. 乳腺癌自然史模型研究系统评价：现状及构建中国人群特异性模型面临的挑战［J］．中华流行病学杂志，2017，38（10）：1419-1425．DOI：10.3760/cma.j.issn.0254-6450.2017.10.025.
MA H L，WANG L，SHI J F，et al. A systematic review of international simulation models on the natural history of breast cancer：current understanding and challenges for Chinese-population-specific model development ［J］．Chin J Epidemiol，2017，38（10）：1419-1425．DOI：10.3760/cma.j.issn.0254-6450.2017.10.025.
［29］FRACHEBOUD J，GROENEWOUD J H，BOER R，et al. Seventy-five years is an appropriate upper age limit for population-based mammography screening［J］．Int J Cancer，2006，118（8）：2020-2025．DOI：10.1002/ijc.21560.
［30］TILANUS-LINTHORST M M，KRIEGE M，BOETES C，et al. Hereditary breast cancer growth rates and its impact on screening policy［J］．Eur J Cancer，2005，41（11）：1610-1617．DOI：10.1016/j.ejca.2005.02.034.
［31］TILANUS-LINTHORST M M，OBDEIJN I M，HOP W C，et al. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch，United Kingdom，and Canadian magnetic resonance imaging screening trials［J］．Clin Cancer Res，2007，13（24）：7357-7362．DOI：10.1158/1078-0432.CCR-07-0689.
［32］KRIEGE M，BREKELMANS C T，BOETES C，et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition［J］．N Engl J Med，2004，351（5）：427-437．DOI：10.1056/nejmoa031759.
［33］BREKELMANS C T，SEYNAEVE C，BARTELS C C，et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk［J］．J Clin Oncol，2001，19（4）：924-930．DOI：10.1200/JCO.2001.19.4.924.
［34］CAUMO F，VECCHIATO F，STRABBIOLI M，et al. Interval cancers in breast cancer screening：comparison of stage and biological characteristics with screen-detected cancers or incident cancers in the absence of screening［J］．Tumori，2010，96（2）：198-201．DOI：10.1177/030089161009600203.
［35］BREKELMANS C T，VAN GORP J M，PEETERS P H，et al.
Histopathology and growth rate of interval breast carcinoma.Characterization of different subgroups［J］．Cancer，1996，78（6）：1220-1228．DOI：10.1002/（sici）1097-0142（19960915）78：6<1220：aid-cncr8>3.0.co；2-d.
［36］NIXON R M，PHAROAH P，TABAR L，et al. Mammographic screening in women with a family history of breast cancer：some results from the Swedish two-county trial［J］．Rev Epidemiol Sante Publique，2000，48（4）：325-331.
［37］CHEN T H，KUO H S，YEN M F，et al. Estimation of sojourn time in chronic disease screening without data on interval cases［J］．Biometrics，2000，56（1）：167-172．DOI：10.1111/j.0006-341x.2000.00167.x.
［38］GENTILI C，SANFILIPPO O，SILVESTRINI R.Cell proliferation and its relationship to clinical features and relapse in breast cancers［J］．Cancer，1981，48（4）：974-979．DOI：10.1002/1097-0142（19810815）48：4<974：aid-cncr2820480420>3.0.co；2-#.
［39］CHARLSON M E，FEINSTEIN A R.Rapid growth rate：a method of identifying node-negative breast cancer patients with a high risk of recurrence［J］．J Chronic Dis，1983，36（12）：847-853．DOI：10.1016/0021-9681（83）90005-x.
［40］REBBECK T R，LEVIN A M，EISEN A，et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers［J］．J Natl Cancer Inst，1999，91（17）：1475-1479．DOI：10.1093/jnci/91.17.1475.
［41］WOHLFAHRT J，ANDERSEN P K，MOURIDSEN H T，et al. Reproductive history and stage of breast cancer［J］．Am J Epidemiol，1999，150（12）：1325-1330．DOI：10.1093/oxfordjournals.aje.a009964.
［42］RYU E B，CHANG J M，SEO M，et al. Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound［J］．Eur Radiol，2014，24（9）：2227-2235．DOI：10.1007/s00330-014-3256-0.
［43］LEE S H，KIM Y S，HAN W，et al. Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography［J］．Medicine （Baltimore），2016，95（37）：e4874．DOI：10.1097/MD.0000000000004874.
［44］YOO T K，MIN J W，KIM M K，et al. In vivo tumor growth rate measured by US in preoperative period and long term disease outcome in breast cancer patients［J］．PLoS One，2015，10（12）：e0144144．DOI：10.1371/journal.pone.0144144.
［45］TABAR L，FAGERBERG G，CHEN H H，et al. Tumour development，histology and grade of breast cancers：prognosis and progression［J］．Int J Cancer，1996，66（4）：413-419．DOI：10.1002/（SICI）1097-0215（19960516）66：4<413：AID-IJC1>3.0.CO；2-Z.
［46］GUNSOY N B，GARCIA-CLOSAS M，MOSS S M.Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom［J］．Breast Cancer Res，2012，14（6）：R152．DOI：10.1186/bcr3365.
［47］MILLET I，BOUIC-PAGES E，HOA D，et al. Growth of breast cancer recurrences assessed by consecutive MRI［J］．BMC Cancer，2011，11：155．DOI：10.1186/1471-2407-11-155.
［48］DEMICHELI R，TERENZIANI M，BONADONNA G.Estimate of tumor growth time for breast cancer local recurrences：rapid growth after wake-up? ［J］．Breast Cancer Res Treat，1998，51（2）：133-137．DOI：10.1023/a：1005887422022.
［49］F?RNVIK D，L?NG K，ANDERSSON I，et al. Estimates of breast cancer growth rate from mammograms and its relation to tumour characteristics［J］．Radiat Prot Dosimetry，2016，169（1/2/3/4）：151-157．DOI：10.1093/rpd/ncv417.
［50］HEUSER L，SPRATT J S，POLK H C.Growth rates of primary breast cancers［J］．Cancer，1979，43（5）：1888-1894．DOI：10.1002/1097-0142（197905）43：5<1888：aid-cncr2820430545>3.0.co；2-m.
［51］GALANTE E，GALLUS G，GUZZON A，et al. Growth rate of primary breast cancer and prognosis：observations on a 3- to 7-year follow-up in 180 breast cancers［J］．Br J Cancer，1986，54（5）：833-836．DOI：10.1038/bjc.1986.247.
［52］TUBIANA M，KOSCIELNY S.Natural history of human breast cancer：recent data and clinical implications［J］．Breast Cancer Res Treat，1991，18（3）：125-140．DOI：10.1007/BF01990028.
［53］ABRAHAMSSON L，CZENE K，HALL P，et al. Breast cancer tumour growth modelling for studying the association of body size with tumour growth rate and symptomatic detection using case-control data［J］．Breast Cancer Res，2015，17：116．DOI：10.1186/s13058-015-0614-z.
［54］BATINA N G，TRENTHAM-DIETZ A，GANGNON R E，et al. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis［J］．Breast Cancer Res Treat，2013，138（2）：519-528．DOI：10.1007/s10549-013-2435-z.

[1]	刘银银, 隋鸿平, 李婷婷, 姜桐桐, 史铁英, 夏云龙. 乳腺癌治疗相关心脏毒性风险预测模型的研究进展[J]. 中国全科医学, 2025, 28(24): 3072-3078.
[2]	罗云昭, 蒋宏传, 徐峰. 基于深度学习模型辅助穿刺病理图像预测乳腺癌新辅助治疗疗效的研究[J]. 中国全科医学, 2025, 28(19): 2407-2413.
[3]	李红梅, 张一民, 王勇, 张育荣, 贾潇, 于晶晶, 桑蝶. 有氧运动改善化疗期间乳腺癌患者体质及生活质量研究：一项随机对照试验[J]. 中国全科医学, 2025, 28(03): 285-292.
[4]	姚珊珊, 马珠月, 史妍妍, 吴雨晴, 张柳柳, 陈明霞, 吴冰, 程芳. 乳腺癌化疗患者心脏毒性风险评估量表的编制和信效度检验[J]. 中国全科医学, 2024, 27(27): 3428-3434.
[5]	陆鑫林, 刘雪薇, 高蓓, 王彦博, 芦文丽. 基于混合方法研究的社区卫生服务中心开展乳腺癌筛查焦点问题分析[J]. 中国全科医学, 2024, 27(19): 2409-2414.
[6]	刘雪薇, 陆鑫林, 钟心媛, 阮占良, 王彦博, 王媛, 芦文丽. 基层医疗卫生机构开展乳腺癌筛查能力评价指标体系构建研究[J]. 中国全科医学, 2024, 27(19): 2415-2420.
[7]	王彦博, 周江涛, 王冰怡, 芦文丽. 基于系统动力学乳腺癌筛查覆盖率促进策略仿真分析[J]. 中国全科医学, 2024, 27(19): 2421-2428.
[8]	刘炳蔚, 王静, 乔雪, 牟思霖, 时光喜, 李静蔚. 雌激素受体阳性乳腺癌患者内分泌治疗期高脂血症的临床特征及中药用药分析：基于真实世界研究[J]. 中国全科医学, 2023, 26(36): 4558-4564.
[9]	李雨荆, 晋一超, 陈醒, 嵇梦颖, 戴辉华. 服用他莫昔芬的乳腺癌患者宫腔镜检出子宫内膜病变的危险因素研究[J]. 中国全科医学, 2023, 26(32): 4026-4030.
[10]	裴蓓, 成琳, 许凌云. 不同新辅助化疗方案对人表皮生长因子受体2阳性乳腺癌患者免疫指标和肿瘤微环境的影响研究[J]. 中国全科医学, 2023, 26(27): 3435-3440.
[11]	付十, 陈晨, 喻梦珠, 金长琴, 何淦, 楚翘, 何亚平. 步行活动对乳腺癌患者情绪健康的潜在影响：创伤后成长不同维度的中介作用研究[J]. 中国全科医学, 2023, 26(17): 2089-2094.
[12]	沈傲梅, 路潜, 符鑫, 韦小夏, 卞静如, 张丽媛, 强万敏, 庞冬. 基于前瞻性队列研究的Meta分析构建乳腺癌相关淋巴水肿风险预测模型研究[J]. 中国全科医学, 2023, 26(17): 2078-2088.
[13]	郑卿勇, 赵亮, 隗伟, 任雪君, 王超, 孙瑞, 丛明华, 于雷, 杨敏. 正念减压疗法可改善乳腺癌患者心理状况：基于系统评价再评价[J]. 中国全科医学, 2023, 26(12): 1503-1512.
[14]	刘雪薇, 王媛, 韦丹梅, 芦文丽. 1990—2019年中国女性乳腺癌发病及死亡趋势的年龄-时期-队列模型分析[J]. 中国全科医学, 2023, 26(01): 34-41.
[15]	孙潇越, 王凤玲, 王爱华. 乳腺癌相关缺血性卒中发病机制及防治的研究进展[J]. 中国全科医学, 2022, 25(29): 3710-3714.